<DOC>
	<DOCNO>NCT02851108</DOCNO>
	<brief_summary>Safety artesunate-amodiaquine combine methylene blue primaquine falciparum malaria treatment African child : A randomised control trial Elimination become goal malaria program increase number endemic country region . As resistance artemisinin compound recently start emerge South-East Asia , clear need develop alternative malaria drug combination . Adding another anti-malarial short half-life methylene blue standard ACT could strategy prevent artemisinin resistance development . Moreover , add gametocytocidal drug ACT reduce probability transmission P. falciparum parasites include drug-resistant parasite . Objectives : The primary objective trial investigate safety artesunate ( AS ) - amodiaquine ( AQ ) - methylene blue ( MB ) compare AS - AQ - primaquine ( PQ ) young child uncomplicated falciparum malaria Burkina Faso .</brief_summary>
	<brief_title>Methylene Blue Against Falciparum Malaria Burkina Faso</brief_title>
	<detailed_description>The overall goal underlie research project develop MB-based first-line drug combination regimen uncomplicated falciparum malaria SSA . The primary objective study : To study safety triple combination AS-AQ-MB compare AS-AQ-PQ treatment uncomplicated falciparum malaria young African child . The secondary objective study : To study efficacy MB-based triple combination comparison standard ACT-PQ treatment uncomplicated falciparum malaria young African child . It mono-center , open randomise control non-inferiority study child uncomplicated falciparum malaria Burkina Faso . Patients randomise two treatment group ( arm ) : 1 . AS-AQ-MB 2 . AS-AQ-PQ Study population : Children age 6-59 month uncomplicated falciparum malaria Nouna Hospital north-western Burkina Faso . Sample size : 100 patient ( 50 per study arm ) . Treatment : The group AS-AQ-MB receive daily fix dose AS-AQ formulation combine daily MB ( 15 mg/kg ) three day period . The control group receive daily fix dose AS-AQ three day combine single dose PQ day 2 ( 0.25 mg/kg ) . Endpoints : Primary endpoint haemoglobin value day 7 compare baseline . Secondary endpoint adverse event ( AE ) , adequate clinical parasitological response ( ACPR ) rate ( PCR-corrected recrudescence ) , well gametocyte prevalence density .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>Weight ≥ 6 kg Uncomplicated malaria cause P. falciparum Asexual parasites ≥ 2 000/µl ≤ 100 000/µl Axillary temperature ≥ 37.5°C history fever last 24 hour Burkinabe nationality Permanent residence study area intention leave surveillance period Written inform consent parent care taker Severe malaria Mixed malaria infection Vomiting ( &gt; 2 time within 24 hour visit ) Any apparent significant disease , include severe malnutrition A history previous , significant adverse reaction know allergy one study drug Anaemia ( haemoglobin &lt; 7 g/dl ) Treated trial All modern antimalarial treatment prior inclusion ( last seven day ) Therapy serotonin reuptake inhibitor ( e.g . citalopram , escitalopram , fluoxetine , Paroxetine , Sertraline ) Simultaneous participation another investigational study Patients know HIV/AIDS disease Therapy drug know inhibit liver enzymes cytochrome 2A6 ( e.g . methoxsalen , pilocarpine , tranylcypromine ) and/or cytochrome 2C8 ( e.g . trimethoprim , ketoconazole , ritonavir , saquinavir , lopinavir , gemfibrozil , montelukast )</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>falciparum malaria</keyword>
	<keyword>sub saharan</keyword>
	<keyword>africa</keyword>
	<keyword>elimination disorder</keyword>
</DOC>